Aravive Announces $10.0 Million Investment by Eshelman Ventures, LLC and Appointment of Dr. Eshelman as Executive Chairman of the Aravive Board of Directors
January 03, 2022 18:15 ET
|
Aravive, Inc.
HOUSTON, Jan. 03, 2022 (GLOBE NEWSWIRE) -- Aravive, Inc. (Nasdaq: ARAV), a late clinical-stage oncology company developing targeted therapeutics to treat metastatic disease today announced that the...
Aravive to Participate in Fireside Chat at Piper Sandler 33rd Annual Virtual Healthcare Conference
November 15, 2021 07:00 ET
|
Aravive, Inc.
HOUSTON, Nov. 15, 2021 (GLOBE NEWSWIRE) -- Aravive, Inc. (Nasdaq: ARAV), a clinical-stage oncology company developing transformative, targeted therapeutics to treat life-threatening cancers, today...
Aravive Announces Positive Preliminary Data from Phase 1b Trial Evaluating Batiraxcept (AVB-500) in Combination with Cabozantinib for Treatment of Clear Cell Renal Cell Carcinoma
November 12, 2021 07:00 ET
|
Aravive, Inc.
7 of 16 (44%) patients achieved best overall response of partial responseConfirmed response in 5 of 7 (71%) patients who had at least 16 weeks of follow-up14 of 16 (88%) patients demonstrated tumor...
Aravive Announces Positive Preliminary Data from Phase 1b Trial Evaluating Batiraxcept (AVB-500) in Combination with Cabozantinib in Clear Cell Renal Cell Carcinoma to be Presented at 2021 Society for Immunotherapy of Cancer Annual Meeting
November 09, 2021 08:00 ET
|
Aravive, Inc.
3 of 5 (60%) patients achieved a partial response All 5 patients treated demonstrated tumor decrease from baselineBatiraxcept has been generally well-tolerated with no dose-limiting toxicitiesAravive...
Aravive Reports Third Quarter 2021 Financial Results and Provides Corporate Updates
October 28, 2021 16:01 ET
|
Aravive, Inc.
Dosed first patient in batiraxcept (formerly AVB-500) Phase 1b clinical trial in pancreatic adenocarcinomaOrphan drug designation granted by European Commission to batiraxcept in platinum resistant...
Aravive to Present New Preliminary Data from Phase 1b Trial Evaluating AVB-500 in Clear Cell Renal Cell Carcinoma at 2021 Society for Immunotherapy of Cancer Annual Meeting
October 01, 2021 08:00 ET
|
Aravive, Inc.
HOUSTON, Oct. 01, 2021 (GLOBE NEWSWIRE) -- Aravive, Inc. (Nasdaq: ARAV), a clinical-stage oncology company developing innovative therapeutics to treat life-threatening diseases, today announced that...
Aravive to Participate in Fireside Chat at Cantor Fitzgerald Virtual Global Healthcare Conference
September 16, 2021 07:00 ET
|
Aravive, Inc.
HOUSTON, Sept. 16, 2021 (GLOBE NEWSWIRE) -- Aravive, Inc. (Nasdaq: ARAV), a clinical-stage oncology company developing innovative therapeutics to treat life-threatening diseases, today announced...
Aravive to Participate in Fireside Chat at H.C. Wainwright 23rd Annual Global Investment Conference
September 01, 2021 07:00 ET
|
Aravive, Inc.
HOUSTON, Sept. 01, 2021 (GLOBE NEWSWIRE) -- Aravive, Inc. (Nasdaq: ARAV), a clinical-stage oncology company developing innovative therapeutics to treat life-threatening diseases, today announced...
Aravive Announces First Patient Dosed in Phase 1b/2 Clinical Trial of AVB-500 for the Treatment of Pancreatic Adenocarcinoma
August 09, 2021 07:00 ET
|
Aravive, Inc.
Trial to Evaluate AVB-500 as a First-Line Treatment in Combination with Gemcitabine and Nab-Paclitaxel Continues Expansion of AVB-500 in Multiple Oncology Indications and Combinations HOUSTON, Aug. ...
Aravive Reports Second Quarter 2021 Financial Results and Provides Corporate Updates
August 05, 2021 07:00 ET
|
Aravive, Inc.
Positive initial results from AVB-500 Phase 1b portion of Phase 1b/2 clinical trial in clear cell renal cell carcinoma; expect to initiate Phase 2 trial in second half of 2021On track to initiate the...